Credit Suisse Ag Kal Vista Pharmaceuticals, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding KALV
# of Institutions
135Shares Held
52MCall Options Held
551KPut Options Held
98K-
Vr Adviser, LLC New York, NY6.25MShares$61 Million8.73% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.91MShares$48 Million1.73% of portfolio
-
Tang Capital Management LLC San Diego, CA4.89MShares$47.8 Million3.11% of portfolio
-
Vestal Point Capital, LP New York, NY4.77MShares$46.6 Million2.4% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$36 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $240M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...